HC Wainwright Reaffirms Buy Rating for Entera Bio (NASDAQ:ENTX)

Entera Bio (NASDAQ:ENTX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $10.00 price objective on the stock.

Other analysts have also issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a research report on Saturday, December 27th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $10.00.

Entera Bio Price Performance

Shares of NASDAQ ENTX opened at $1.45 on Monday. The company has a market capitalization of $66.50 million, a P/E ratio of -5.80 and a beta of 1.84. The company has a 50 day simple moving average of $1.71 and a 200-day simple moving average of $2.03. Entera Bio has a 1 year low of $1.00 and a 1 year high of $3.22.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. As a group, research analysts expect that Entera Bio will post -0.28 EPS for the current year.

Institutional Trading of Entera Bio

Hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC boosted its stake in shares of Entera Bio by 243.0% in the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after purchasing an additional 28,322 shares during the period. HighTower Advisors LLC increased its stake in Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after buying an additional 25,000 shares during the period. Finally, Bessemer Group Inc. acquired a new stake in Entera Bio during the 2nd quarter worth approximately $268,000. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.